Background. Imiquimod, a synthetic Toll-like receptor 7 agonist enhanced immunogenicity of influenza vaccine in a mouse model. We hypothesized that topical imiquimod before intradermal influenza vaccination (TIV) would produce similar effect in human.
Influenza poses a heavy burden to our healthcare systems [1, 2] . Seasonal, zoonotic, and pandemic influenza are constant global threats. The World Health Organization (WHO) estimates that seasonal influenza causes 250 000-500 000 deaths worldwide annually, with an even higher mortality during the pandemic periods [3] . Moreover, zoonotic influenza such as the avianorigin H5N1 and the H7N9 influenza are associated with a much higher mortality than seasonal influenza [4, 5] . Elderly persons with comorbidities are at the highest risk of hospitalization for influenza infection and its complications. Vaccine immunogenicity among these at-risk individuals is suboptimal due to immunosenescence [6] . Various strategies including intradermal vaccination and new vaccine adjuvants have been shown to improve immunogenicity [7, 8] . Experience with the A(H1N1)pdm09 vaccine showed that mass production of an antigen-matched effective monovalent vaccine took at least 6 months from manufacture to delivery [9] and another 3 weeks to mount a seroprotective response after vaccination. Therefore, any strategy for expediting or augmenting the protective immune response from influenza vaccine would be especially important in the outbreak setting.
Recently, imiquimod, a synthetic Toll-like receptor 7 (TLR7) agonist used for the treatment of DNA virus infection, was shown to improve vaccine immunogenicity against influenza virus in a mouse model [10, 11] and for other infections including human immunodeficiency virus (HIV) [12] , human papillomavirus (HPV) [13] , and malaria [14] . The objective of this prospective, double-blind, randomized, controlled trial was to evaluate the effectiveness and safety of topical treatment with imiquimod immediately before intradermal influenza vaccination. Our a priori hypothesis was that imiquimod pretreatment would expedite and augment the immunogenicity of influenza vaccination.
METHODS

Study Participants
Between January 2012 and March 2012, adults aged ≥21 years attending the medical specialist outpatient clinics (SOPCs) in the Hong Kong West Cluster hospitals who satisfied the WHO recommendations and indications for influenza vaccination were screened for eligibility. The majority were elderly persons aged ≥65 years with comorbidities. Participants were included if they had not received the influenza vaccine in the prior 3 months and gave written informed consent. Participants with clinically significant immune-related diseases on long-term immunosuppressants and with a history of allergy to the vaccines' components were excluded. The eligibility criteria are listed in the Supplementary Appendix. The study was approved by the institutional review board of the University of Hong Kong and Hospital Authority and is registered with ClinicalTrials.gov (NCT01508884).
Study Design and Interventions
At the time of inclusion, the participants' demographic and clinical characteristics were recorded. Simple randomization with no stratification was performed. Participants were randomly assigned to the experimental group deltoid region of the right arm of all participants. In the IQ group, the study nurse applied the contents of 1 sachet of Aldara (5% cream containing 250 mg of imiquimod) to the marked surface on the skin 5 minutes before vaccination. In the INT and IM groups, aqueous cream British Pharmacopoeia (BP) (AFT Pharmaceuticals, New Zealand) was applied instead of Aldara. Both creams were indistinguishable by the untrained eye; the aqueous cream BP is inert and has no adverse effect on post-vaccination immune response. The vaccine was injected in the center of the marked area after the cream was fully absorbed. Participants removed the ointment (Aldara or aqueous cream BP) by washing with tap water after 6 hours.
To maintain blinding, each participant was assigned a serial number, and the randomization list linked each serial number with the 3 study groups, which differed by the route of delivery and the type of pretreatment ointment applied. Only the study nurse responsible for giving the vaccination, who did not take part in the analysis, had knowledge of the type of topical treatment applied. Both patients and investigators remained blinded to the type of topical treatment applied until completion of the study. The route of vaccine delivery was unblinded.
Influenza Vaccine
Intradermal Intanza and the intramuscular Vaxigrip influenza vaccines were used in this study ( The intradermal injection device, the Becton Dickinson (BD) Soluvia microinjection system, consists of a prefilled TIV, with a single 1.5-mm needle that penetrates perpendicularly into the skin [7] . The BD Soluvia is currently the only prefilled intradermal device licensed for influenza vaccine.
Safety was evaluated by asking the participants to remain on the clinic premise for 30 minutes for observation post-immunization. An immediate adverse event checklist was completed before discharge. Participants were given a diary to document symptoms of local and systemic adverse events that occurred within the first 7 days post-vaccination. Systemic symptoms included fever (body temperature ≥37.5°C), headache, malaise, myalgia, arthralgia, and severe adverse events. Local symptoms included redness, swelling, induration, ecchymosis, and pain. Redness, swelling, induration, and ecchymosis were graded based on size as follows: grade 1 <20 mm and grade 2 ≥20 mm. Pain was graded as follows: grade 1 was pain on touch and grade 2 was pain when arm was moved [7] .
Immunogenicity Measurements
Blood was taken from participants at baseline; 7, 14, and 21 days; and 1 year after vaccination for antibody assay. Serum antibody titers were measured using hemagglutination-inhibition (HI) and microneutralization (MN) assays according to standard methods as described previously [15, 16] . The Committee for Proprietary Medicinal Products (CPMP) guidelines of the 
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Abbreviation: IQR, interquartile range. European Medicines Evaluation Agency were adopted for immunogenicity measurements of the HI assay. A satisfactory antibody response in the elderly cohort is based on the following: >60% achieving a HI titer of ≥40 (seroprotection rate), a geometric mean titer (GMT) increase of >2-fold, or >30% achieving a 4-fold rise in antibody titer (seroconversion rate) [17] . For the MN assay, the GMT of the 3 influenza strains was compared among the 3 groups. The primary outcome measure was the seroconversion rate by HI assay on day 7. Secondary outcome measures included GMT, GMT-fold increases, and the seroprotection rate by HI assay and the GMT by MN assay from day 7 to 1 year The CPMPs guidelines for an elderly cohort state that at least 1 of the following criteria must be met for the viral strain in the vaccine: GMT-fold increase >2, seroconversion rate >30%, or seroprotection rate >60%. Significant P values are indicated by bold type.
Abbreviations: CI, confidence interval; CPMP, Committee for Proprietary Medicinal Products; GMT, geometric mean titer.
post-vaccination. The seroconversion rate by HI assay from day 14 to 1 year and adverse events post-vaccination were also compared among the 3 groups.
Clinical Efficacy
All enrolled patients were followed prospectively for 1 year after vaccination. Hospitalization for pneumonia or influenza, according to International Classification of Diseases, Ninth Revision, Clinical Modification inpatient codes (codes 480-487), was recorded [18] . Clinical details defined according to the ICD-9-CM codes, the Charlson comorbidity index [19] , vaccination and medical history, and length of hospitalization were retrieved from the computerized medical system. Diagnosis of influenza A or B infection was confirmed by immunofluorescence assay (IMAGEN, Oxoid Ltd, Ely, UK) on nasopharyngeal aspirate (NPA) as previously described [20] .
Statistical Analysis
We estimated the sample size of this study based on a previous influenza vaccination study on elderly patients with comorbidities [7] . We assumed the seroconversion rate of the IQ group to be superior to that of the control IM group. Also, we assumed the seroconversion rate for the H1N1 strain by the intradermal and intramuscular TIV to be 25% and 6%, respectively. With a power of 80% and a 1-sided type 1 error of 5%, 30 participants would be needed for each treatment arm that would also allow for a loss to follow-up rate of 10%. Analysis of variance was used to compare demographic parameters, immunogenicity, and clinical efficacy among the 3 groups. Log-rank test was used to compare the cumulative hospitalization rate over a 1-year period after vaccination. SPSS Statistics 20.0 (IBM) was used for statistical computation. A P value < .05 was considered to represent a significant difference.
RESULTS
Subjects
A total of 762 patients who attended the SOPCs were screened between January 2012 and March 2012 (Figure 1 ). Three hundred thirty patients had received the influenza vaccine in the prior 3 months, and 339 patients declined to participate in the study. The remaining 93 participants were enrolled. Thirty-one participants were randomized to the experimental IQ group, 30 to the control IM group, and 32 to the control INT group. Two participants, 1 from the IQ group and 1 from the INT Significant P values are indicated by bold type.
Abbreviations: CI, confidence interval; GMT, geometric mean titer.
group, refused to return for the day 7 blood draw and were withdrawn from the study. Data for the remaining 91 participants were analyzed. All 3 groups were comparable in terms of the baseline demographics (Table 1) . Twenty-four (26.4%) recruited participants were elderly home residents. None of the participants were bedridden, on home oxygen therapy, on percutaneous endoscopic gastrostomy or nasogastric tube feeding, had a history of splenectomy, or had recently used antibiotics.
Immunogenicity by Hemagglutination Inhibition Assay
Of the participants in the IQ group, 90% and 96.7% achieved seroconversion and seroprotection, respectively, against the H1N1 strain by day 7, with a GMT-fold increase of 16.8 (95% confidence interval, 7.1-26.5; Table 2 ). The day 7 seroconversion rate, seroprotection rate, and GMT-fold increase for the H1N1 strain was significantly higher in the IQ group than in the 2 controls (P < .001, P = .002, and P < .001, respectively).
The better immunogenicity in all 3 parameters was sustained from day 7 to year 1. The day 7 seroconversion rate of the H3N2 and B strains was also significantly higher in the IQ group from day 7 to year 1 (P ≤ .001). All CPMP criteria of seroconversion, seroprotection, and GMT-fold increase in the 3 influenza strains were met in the IQ group at least 2 weeks earlier than both controls. Significant P values are indicated by bold type.
Abbreviation: NPA, nasopharyngeal aspirate.
Immunogenicity by Microneutralization Assay
Similar to the HI assay results, the GMT by MN assay for the 3 strains was significantly higher in the IQ group (Table 3) from day 7 to year 1 (P < .01), with the exception of the B strain at year 1.
Clinical Efficacy
Significantly fewer participants in the IQ group were hospitalized for pneumonia or influenza (P < .05; Table 4 ). Fewer positive NPAs for influenza A were detected in the IQ group (P < .05). Log-rank test showed that participants in the IQ group had significantly lower cumulative hospitalization rates for pneumonia or influenza over a 1-year period after vaccination (P = .03) when compared with the 2 controls.
Safety
No deaths or serious adverse events related to vaccination were reported ( Table 5 ). The incidence of systemic adverse events was infrequent and self-limiting. Although systemic symptoms occurred more frequently in the intradermal than the intramuscular vaccinees, the difference remained insignificant. Local symptoms during post-vaccination, including grade 2 redness (P < .001) and grade 1 swelling (P = .001), were significantly more common in the IQ group. All events were mild to moderate in intensity and were transient. None of the participants developed leakage, post-inflammatory pigmentation, or other long-term side effects after vaccination.
DISCUSSION
Here, we report the results of the first double-blind, randomized, controlled trial on intradermal TIV with topical pretreatment with imiquimod, a potent TLR7 agonist. Application of imiquimod prior to intradermal vaccination expedited and augmented the immunogenicity of influenza vaccination in elderly participants. By day 7 of vaccination, seroconversion, GMT, and GMT-fold increase against the 3 influenza strains were significantly higher in the imiquimod group than in both controls. The 3 criteria of seroconversion, seroprotection, and GMTfold increase were met in the imiquimod group at least 2 weeks earlier than in the other groups. The better seroconversion rate of the imiquimod group in all 3 influenza strains was sustained from day 7 to year 1, and, more importantly, translated into better clinical efficacy, as proven by the lower cumulative hospitalization rate for pneumonia or influenza and fewer positive NPA samples for influenza A in the imiquimod group. This would offer robust protection against the 3 influenza strains, especially to H3N2 and influenza B virus, which caused the highest influenza-associated mortality among people aged ≥65 years [21] . The overall hospitalization rates for pneumonia or severe influenza were high because most of the recruited participants were elderly home residents.
This dual effect in expediting and augmenting the humoral response to TIV in the imiquimod group was likely to be a synergism between TLR7 activation and the intradermal vaccination. This enhanced humoral response was associated with higher incidence of post-vaccination local inflammation of redness, swelling, and fever (statistically insignificant) in the study group [22] , with no long-term sequelae. One could argue that contending with the self-limiting local reactions plus minor systemic reactions in the imiquimod group against a more rapid onset and significantly more robust immune response over the course of 1 year would be worthwhile. Nevertheless, reducing the concentration of imiquimod from 5% to 3.75% or 2.5% may circumvent these local and systemic adverse events.
In recent years, various strategies for improving the immunogenicity of seasonal influenza vaccination in at-risk populations have been studied [23, 24] . Elderly individuals suffer from immunosenescence, resulting in reduced numbers of Langerhans cells, decreased capacity of dendritic cells to present antigen, and defective or reduced expression of TLRs and major histocompatibility complex molecules [25] . Skin-based vaccinations with various novel intradermal delivery devices have been shown to overcome immunosenescence by effectively stimulating the remaining dermal Langerhans and dendritic cells, with dose-sparing effect in influenza vaccination [7, 26] . In this study, the use of imiquimod as an adjuvant further enhanced T-cell and antibody responses through improved antigen presentation, activation, and maturation of dendritic cells. In view of the stimulation of the cellular immune pathway, direct measures of the cell-mediated immunity with granzyme B and interferon/interleukin-10 ratio, as suggested by McElhaney et al [27] , may have a better correlation of vaccine immunogenicity compared with antibody responses in the elderly.
Traditional oil-based MF59 and the aluminum-based adjuvant vaccines were effective in healthy adults but less immunogenic in the elderly. The lipid content of the MF59 adjuvant is also unsuitable for intradermal vaccination. When compared with an AS03-adjuvanted A(H1N1)pdm09 vaccine, the seroconversion rate by the imiquimod and intradermal vaccination for individuals aged >64 years was significantly higher on day 21 (93.3% vs 75.3%) and at 6-12 months (86.7% vs 34.9%) [28] . Novel vaccine adjuvants that target pattern recognition receptors, which include TLRs [29] and nucleotide-binding oligomerization domain receptors [30] , activate the innate immunity by recognizing and binding to pathogen-associated molecular patterns conserved in pathogens. TLRs are a class of proteins that play an essential role in the innate immune system. They are membrane-spanning and noncatalytic receptors usually expressed in macrophages and dendritic cells. The natural ligand for TLR7 is a single-stranded RNA located in the RNA viral genome. Topical TLR7 agonist has also been used extensively in the treatment of DNA virus infection including HIV and HPV, and in the prevention of herpes simplex infection recurrence [12, 13, 31] . In this study, we applied the topical imiquimod, a low-weight synthetic imidazoquinolone amine analogue, which stimulates TLR7 by upregulation of HLA molecules, thereby activating the dendritic cell presentation of the 3 influenza vaccine antigens. Imiquimod also induces proinflammatory cytokine production and stimulation of T-helper cells. TLR7 plays an important part in the induction of adaptive immune response by enhancing antibody-producing B-cell differentiation, by facilitating antibody isotype class switching, and, more importantly, by increasing B-cell memory [32] . Imiquimod may also act via a TLR-independent adenosine receptorsignaling pathway.
Previous studies have strongly supported the local immuneboosting effect of imiquimod in animal models. Microneedle delivery of imiquimod with influenza subunit vaccine induced improved immune responses in BALB/c mice [10] . The imiquimod-adjuvanted vaccine elicited higher levels of immunoglobulin-G2a antibodies, HI titers, and interferon-gamma cellular response compared with vaccine alone. Topical delivery of imiquimod into a mouse model as adjuvant for HIV DNA vaccination was also effective [12] . However, intradermal hepatitis B vaccination in nonresponders after topical application of imiquimod failed to enhance the humoral response [33] . The reasons were likely related to the participants in that study who were known nonresponders with a predisposed immune defect at the cellular level, which could not be improved by activating the antigen presentation. Also, the lack of an effective and reliable prefilled intradermal delivery device such as the BD Soluvia microinjection system and small sample size might have affected the result.
The importance of our findings is highlighted by the frequent antigenic drift of the influenza virus and the constant threat of an influenza pandemic from avian-origin H5N1 or more recently the H7N9 viruses [4, 5] . During the 2009 influenza pandemic, the specific vaccine was not available in most countries before the first wave of infection [34] . Currently, no vaccination strategy has been shown to be immunogenic within the first week of vaccination. The immunization strategy demonstrated in this study by topical pretreatment with imiquimod before intradermal vaccination is a highly flexible, safe, and inexpensive way to induce rapid and sustained immunity against the new virus in serologically naive or elderly individuals with comorbidities. Other intradermal microneedle methods could be adapted to the intramuscular vaccines in pandemic situations [7, 23] . Further study of the novel avian strains is necessary to determine whether a similar response would be observed in unprimed animal models.
The limitation of this study is that the majority of recruited patients were elderly, targeted by the influenza vaccination program promoted by the Center for Health Protection in Hong Kong [35] . Extra clinic visits for blood draws required by this study also deterred the elderly participants from joining, resulting in a relatively small sample size. We therefore could not completely eliminate the factor of chance. Further studies on healthy adults with a negative control, and on other live attenuated and protein-based vaccines, is clearly warranted to test the immunogenicity and range of adverse events potentially caused by this local adjuvant.
In conclusion, pretreatment with topical imiquimod significantly expedited, augmented, and prolonged the immunogenicity of influenza vaccination. This strategy for influenza immunization should be considered for elderly populations.
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